The Tagrisso train rolls on for AstraZeneca. The British pharma giant’s oncology unit recently launched its first direct-to-consumer US commercial supporting Tagrisso (osimertinib) to help lung cancer ...
Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...
SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...
AstraZeneca and celebrity chef Ming Tsai are teaming up for an online cooking session peppered with lung cancer information. A Facebook video features Tsai and his son Henry preparing a healthy ...
On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed ...
Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results